ARTICLE | Clinical News
Bremelanotide: Phase III started
January 19, 2015 8:00 AM UTC
Palatin began the 32-week, double-blind, placebo-controlled, North American Phase III reconnect study to evaluate subcutaneous bremelanotide self-administered as needed in about 550 premenopausal wome...